Your session is about to expire
← Back to Search
Cross-Linked HA Device
Dermal Filler - Aline HA for Soft Tissue Disorder
N/A
Waitlist Available
Led By Nowell Solish, MD
Research Sponsored by TauTona Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
The protocol hypothesis is that treatment with Aline HA™ will be safe through 6 months as determined by clinical assessment of treatment sites and routine tracking of adverse events.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Assessment of Treatment Site Responses Post Procedure
Secondary study objectives
Number of Participants With a Decrease in the Wrinkle Severity Scale for Nasolabial Folds
Percentage of Participants That Were Satisfied With the Treatment as Rated by GAIS
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Dermal Filler - Aline HAExperimental Treatment1 Intervention
Single armed study
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aline HA
2012
N/A
~80
Find a Location
Who is running the clinical trial?
TauTona GroupLead Sponsor
3 Previous Clinical Trials
60 Total Patients Enrolled
Nowell Solish, MDPrincipal Investigator
2 Previous Clinical Trials
66 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger